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Objectives

•
The Antineutrophil cytoplasmic antibody (ANCA) were first described in 1982 [1] , divided into 2 major categories; one is perinuclear (p-) ANCA and the second is a cytoplasmic (c-) ANCA. The main epitope of p-ANCA is myeloperoxidase (MPO-ANCA) [2] .
• MPO-ANCA is known as a serologic marker for several diseases including microscopic polyangiitis (MPA), Churg-Strauss syndrome (CSS), and rapidly progressive glomerulonephritis (RPGN) [3] [4] [5] [6] .
• While several studies in patients with MPA, CSS, and RPGN have been reported, there appear to be no reports on CT findings in patients with elevated MPO-ANCA other than MPA, CSS, and RPGN. Therefore aim of this study was to review and analyze the chest CT findings between patients with classified disease as MPA, CSS and RPGN, and patients with no underlying disease.
Patients
1) The authors retrospectively reviewed the pulmonary CT scans of 149 patients with serum evidence of MPO-ANCA and who had undergone chest CT scans (within a month of being found positive for MPO-ANCA) between January 1996 and Marh 2010 (Table 1) .
2) Patients with infectious disease or tumor were excluded.
CT Image Interpretation
1) The CT scans were randamized and then retrospectively reviewed by two chest radiologists who were aware of the underlying diagnoses.
2) The parenchymal, pleural, and mediastinal abnormalities were assessed.
The observers reached conclusions by consensus.
Statistical Analysis
Statistical analyses of the incidence of symptoms were conducted using Fisher' s exact test and the #2 test. 
Results
•
The frequencies of CT findings are summarized in Table 2 and 3. • Of the 149 patients with serum evidence of MPO-ANCA, the most common CT findings were ground-glass attenuation found in 110 patients (74%, n=149) (Figure 1-3) , followed by consolidation in 52 patients (35%) (Figure1and 2), traction bronchiectasis in 46 patients (31%), honey combing in 46 patients (31%)( figure 3 and 4) , and interlobular septal thickening in 37 patients (25%) (Figure 1 ).
• By comparison with the patients with classified disease and the patients with unclassified disease, consolidation, bronchial wall thickening, interlobular septal thickening, nodules, and pleural effusion were more frequently observed in patients with classified disease than in those with unclassified disease. In contrast, honeycombing was more frequently observed in patients with unclassified disease than in those with classified disease.
